Company Profile
Novavax Stock Price, News & Catalysts
- Ticker:
- NVAX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
11.32 USD (-9.87%)
Close
Last updated: October 6, 2026
1.68B USD
Market cap
Why the stock is moving
As of Oct 6, 2026, NVAX closed down 9.87% at $11.32. No new same-company headline was identified in the current news window.
Company overview
Protein-Based Vaccine Technology Company
Novavax develops vaccines using recombinant protein nanoparticles and its Matrix-M adjuvant. The platform is designed to generate strong immune responses while using established protein-based manufacturing and formulation approaches.
COVID-19 Vaccine Franchise
Nuvaxovid is the company's protein-based COVID-19 vaccine and the principal validation of its commercial platform. Novavax has shifted much of the product's global commercialization and development to Sanofi while retaining milestone and royalty economics.
Matrix-M Adjuvant Platform
Matrix-M is used to enhance immune responses and can be paired with antigens from Novavax or external partners. Its use in the R21/Matrix-M malaria vaccine and multiple partnered programs gives the company exposure to infectious-disease and oncology vaccines beyond products it develops alone.
Partnered Commercial Model
The Sanofi relationship combines Novavax's vaccine technology with a larger global development, manufacturing, and commercial infrastructure. This structure reduces Novavax's direct operating burden while preserving participation through upfront payments, milestones, royalties, and supply-related economics.
Internal Development Pipeline
Novavax continues to maintain internal vaccine research, including a Clostridioides difficile program, while evaluating additional uses of Matrix-M. The company can also license its platform to partners developing vaccines for infectious diseases or therapeutic applications.
Future catalysts
- Initiation of Sanofi's Phase 3 study of a combined COVID-19 and influenza vaccine following regulatory alignment.
- Completion of the Nuvaxovid manufacturing technology transfer to Sanofi around mid-2027.
- Potential clinical entry of Novavax's Clostridioides difficile vaccine program as early as 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Novavax (NVAX)?
Novavax (NVAX) most recently closed at 11.32 USD, a -9.87% move versus the previous session.
What is the market cap of Novavax (NVAX)?
Novavax currently has a market capitalization of 1.68B USD on BioPharmSignal.
What does Novavax do?
Protein-Based Vaccine Technology Company Novavax develops vaccines using recombinant protein nanoparticles and its Matrix-M adjuvant. The platform is designed to generate strong immune responses while using established protein-based manufacturing and formulation approaches. COVID-19 Vaccine Franchise Nuvaxovid is the company's protein-based COVID-19 vaccine...
On which exchange is NVAX stock listed?
Novavax (NVAX) is associated with NASDAQ, United States, Biopharma.
What is COVID-19?
Initiation of Sanofi's Phase 3 study of a combined COVID-19 and influenza vaccine following regulatory alignment.
Which conditions is Novavax targeting with COVID-19?
Novavax is associated with oncology based on its company overview and current catalyst commentary.
How does Novavax describe recent progress with COVID-19?
Initiation of Sanofi's Phase 3 study of a combined COVID-19 and influenza vaccine following regulatory alignment.
What is Protein-Based?
Protein-Based Vaccine Technology Company Novavax develops vaccines using recombinant protein nanoparticles and its Matrix-M adjuvant.